Cosmo Bio Company,Limited
FY2026 December Quarter 2 Interim Consolidated Financial Results [Japanese GAAP] (Consolidated)
The interim consolidated results for the six months ended December 2026 show net sales of 5,914 million yen (YoY +9.5%), operating income of 279 million yen ( +1.2%), ordinary income of 340 million yen (△0.8%), and net income attributable to owners of the parent of 277 million yen (YoY +10.5%). Full-year guidance unchanged, dividend forecast unchanged. An earnings presentation is planned.
Key Figures
- Net sales: 5,914 million yen (YoY +9.5%)
- Operating income: 279 million yen (YoY +1.2%)
- Net income attributable to owners of the parent: 277 million yen (YoY +10.5%)
AI要約
Business Performance Summary
Cosmo Bio’s FY2026 2nd quarter (six months ended) results show net sales of 5,914 million yen, up 9.5% YoY, operating income of 279 million yen with a slight increase, ordinary income of 340 million yen, down slightly YoY, and net income attributable to owners of the parent of 277 million yen, up 10.5% YoY. By product, research reagents accounted for 4,694 million yen and instruments for 1,219 million yen. The average foreign exchange rate was around 155 yen per dollar. There are no changes to the full-year earnings guidance or dividend expectations, and an earnings presentation is planned.
Financial Position and Capital Structure
Total assets amount to 12,844 million yen, net assets 10,349 million yen, and the equity ratio remains high at 76.0%. Cash and deposits increased from the beginning of the term, notes receivable decreased, and marketable securities increased. Liabilities totaled 2,494 million yen, down versus the previous term. Treasury stock holdings are 350,079 shares, and shareholders' equity stands at 7,853 million yen.
Cosmo Bio Co., Ltd.
Company overview · Stock price · Financial data · All IR
